Mabwell Receives FDA Clearance for 9MW5211 Clinical Trial Targeting Inflammatory Bowel Disease and Advances Global Autoimmune Therapy Pipeline
Mabwell (Shanghai) Bioscience Receives FDA Clearance for Cli...
Sign in to continue:
Mabwell (Shanghai) Bioscience Receives FDA Clearance for Cli...
Details and Implications for Shareholders Background: C...
Shenzhen LDROBOT Co., Ltd. Announces Allotment Results and K...
China Isotope & Radiation Corporation Announces Key Internat...
JBB Builders Signs Strategic MOU to Explore Southeast Asian ...
Hesai Group Announces Record Date for 2026 Annual General Me...
Zhongliang Holdings Group - April 2026 Operating Update ...
Synertone Communication Corporation Announces Poll Results o...
Ab&B Bio-Tech Receives Key Regulatory Approvals for mRNA RSV...
International Business Settlement Holdings Limited - Settlem...